EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation

Yangyang Huang, Xujiao Zhou, Yirou Zhang, Miao Xie, Fujun Wang, Jingcan Qin, Han Ye, Hong Zhang, Chuan Zhang iD, Jiaxu Hong

Advanced Science · 2024-04 · 11 (13)

DOI: 10.1002/advs.202306248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.01.2024. Verfasst von Yangyang Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Key Laboratory for Molecular Engineerin…. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Nucleic Acids. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Medical Innovation Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein degradation techniques, such as proteolysis‐targeting chimeras (PROTACs) and lysosome‐targeting chimeras (LYTACs), have emerged as promising therapeutic strategies for the treatment of diseases. However, the efficacy of current protein degradation methods still needs to be improved to address the complex mechanisms underlying diseases. Herein, a LYTAC Plus hydrogel engineered is proposed by nucleic acid self‐assembly, which integrates a gene silencing motif into a LYTAC construct to enhance its therapeutic potential. As a proof‐of‐concept study, vascular endothelial growth factor receptor (VEGFR)‐binding peptides and mannose‐6 phosphate (M6P) moieties into a self‐assembled nucleic acid hydrogel are introduced, enabling its LYTAC capability. Small interference RNAs (siRNAs) is then employed that target the angiopoietin‐2 (ANG‐2) gene as cross‐linkers for hydrogel formation, giving the final LYTAC Plus hydrogel gene silencing ability. With dual functionalities, the LYTAC Plus hydrogel demonstrated effectiveness in simultaneously reducing the levels of VEGFR‐2 and ANG‐2 both in vitro and in vivo, as well as in improving therapeutic outcomes in treating neovascular age‐related macular degeneration in a mouse model. As a general material platform, the LYTAC Plus hydrogel may possess great potential for the treatment of various diseases and warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor ANucleic AcidsMiceAnimalsDown-RegulationRNA, Small InterferingHydrogels

Stichwörter der Autor:innen

LYTACsnuclear acid hydrogeln‐AMDprotein degradationsiRNA

Substanzen

Vascular Endothelial Growth Factor ANucleic AcidsRNA, Small InterferingHydrogels

Autor:innen und Institutionen

  • School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai, 200240, P.…
  • Department of Ophthalmology and Vision Science, Shanghai Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, 200030, P. R. China.
  • Department of Radiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, P. R. China.
  • Department of Ophthalmology, the Affiliated Hospital of Guizhou Medical University, Guiyang, 550025, P. R. China.
  • Shanghai Engineering Research Center of Synthetic Immunology, Shanghai, 200032, China.

ORCID-Profile: Chuan Zhang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Medical Innovation Research Program
  • Shanghai Key Clinical Research Program
  • Basic Research-Shanghai Jiao Tong University
  • Natural Science Foundation of Shandong Province
  • Shanghai Science and Technology Innovation Program

Zitieren

APA

Huang, Y., Zhou, X., Zhang, Y., Xie, M., Wang, F., Qin, J., Ye, H., Zhang, H., Zhang, C., & Hong, J. (2024). A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation. Advanced Science, 11(13). https://doi.org/10.1002/advs.202306248

Vancouver

Huang Y, Zhou X, Zhang Y, Xie M, Wang F, Qin J, et al. A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation. Advanced Science. 2024;11(13). doi:10.1002/advs.202306248

BibTeX
@article{Huang2024,
  author = {Huang, Yangyang and Zhou, Xujiao and Zhang, Yirou and Xie, Miao and Wang, Fujun and Qin, Jingcan and Ye, Han and Zhang, Hong and Zhang, Chuan and Hong, Jiaxu},
  title = {A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {13},
  doi = {10.1002/advs.202306248}
}
Kostenlos starten →